Cargando…

Convalescent plasma in the management of COVID-19 pneumonia

Detalles Bibliográficos
Autores principales:	Elbadawi, Ayman, Shnoda, Mina, Laguio-Vila, Maryrose, Mamas, Mamas A., Elgendy, Islam Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Federation of Internal Medicine. Published by Elsevier B.V. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084607/ https://www.ncbi.nlm.nih.gov/pubmed/33966929 http://dx.doi.org/10.1016/j.ejim.2021.04.016

Ejemplares similares

Role of oesophageal cooling in the prevention of oesophageal injury in atrial fibrillation catheter ablation
por: Hamed, Mohamed, et al.
Publicado: (2023)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

The Landscape of Medical Literature in the Era of COVID-19: Original Research Versus Opinion Pieces
por: Elgendy, Akram Y., et al.
Publicado: (2020)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

‘Treatment of COVID-19 with convalescent plasma’ – Author’s reply
por: Wooding, Denise J., et al.
Publicado: (2021)

Use of convalescent plasma in COVID-19 patients in China
por: Zhu, M., et al.
Publicado: (2020)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors
por: Bansal, N., et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Intravenous iron therapy among patients with heart failure and iron deficiency: An updated meta-analysis of randomized controlled trials
por: Hamed, Mohamed, et al.
Publicado: (2023)

Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Farag, Youssef M.K.
Publicado: (2020)

Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation
por: Hashim, H.T.
Publicado: (2020)

Challenges in the production of COVID-19 convalescent plasma- analysis of donor recruitment
por: Sekiya, Eliseo Joji, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
por: De Santis, Gil C., et al.
Publicado: (2022)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

COVID-19convalescent plasma use in the oncology and geriatric patients: Ethical aspects in transfusion medicine
por: Bansal, N., et al.
Publicado: (2022)

Convalescent plasma for patients with COVID-19
por: Zeng, Furong, et al.
Publicado: (2020)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

Covid-19 convalescent plasma and SARS-CoV-2 viral variants
por: Joob, B., et al.
Publicado: (2021)

Convalescent plasma: A possible treatment of COVID-19 in India
por: Teixeira da Silva, Jaime A.
Publicado: (2020)

1461. Impact of the Ampicillin/Sulbactam Shortage on Antibiotic Prescribing and Clinical Outcomes for Adult Inpatients with Aspiration Pneumonia
por: Staicu, Mary L, et al.
Publicado: (2020)

Invasive Management for Non–ST‐Segment–Elevation Myocardial Infarction and Chronic Kidney Disease: Does One Size Fit All?
por: Elbadawi, Ayman, et al.
Publicado: (2022)

Antimicrobial stewardship programs and convalescent plasma for COVID-19: A new paradigm for preauthorization?
por: Stevens, Michael P., et al.
Publicado: (2020)

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
por: London, Jonathan, et al.
Publicado: (2020)

Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?
por: Basic-Jukic, Nikolina
Publicado: (2020)

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
por: Vuk, T., et al.
Publicado: (2021)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

What are the hurdles in the pathway of COVID-19 convalescent plasma collection in low-income nations?
por: Mukhida, Sahjid, et al.
Publicado: (2023)

Convalescent plasma for covid19 – How long should a donor be excluded from donation?
por: Kutner, Jose M., et al.
Publicado: (2020)

Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin
por: Gazzaruso, Carmine, et al.
Publicado: (2021)

A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma
por: Iaboni, Aled, et al.
Publicado: (2021)

Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia
por: McKemey, Emily, et al.
Publicado: (2021)

Convalescent plasma therapy in COVID 19: Every dark cloud has a silver lining
por: Deokar, Kunal, et al.
Publicado: (2020)

The true historical origin of convalescent plasma therapy
por: Marson, Piero, et al.
Publicado: (2020)

Reply to “Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link”
por: Elgendy, Islam Y., et al.
Publicado: (2021)

Second Decline in Admissions With Heart Failure and Myocardial Infarction During the COVID-19 Pandemic
por: Wu, Jianhua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5ievhjedjr9jtk6muljmo0n9i7